Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Viveve announces FDA approval to conduct PURSUIT trial » 08:31
07/07/20
07/07
08:31
07/07/20
08:31
VIVE

Viveve

$0.57 /

+0.0088 (+1.56%)

Viveve Medical announced…

Viveve Medical announced that the Company has received approval of its Investigational Device Exemption, or IDE, from the FDA to begin a stress urinary incontinence, or SUI, multicenter, randomized, double-blinded, sham-controlled clinical trial entitled PURSUIT - Prospective U.S. Radiofrequency SUI Trial. Viveve said in a release, "The trial is designed to evaluate the safety and efficacy of Viveve's Cryogen-cooled Monopolar Radiofrequency, or CMRF, treatment versus an inert sham tip for the improvement of SUI in women. In April VIVEVE announced resubmission of the SUI IDE to the FDA to conduct the PURSUIT Trial. In May, the FDA outlined several study considerations that were successfully addressed in an IDE Supplement that VIVEVE submitted to the FDA on June 1."

ShowHide Related Items >><<
VIVE Viveve
$0.57 /

+0.0088 (+1.56%)

VIVE Viveve
$0.57 /

+0.0088 (+1.56%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
VIVE Viveve
$0.57 /

+0.0088 (+1.56%)

Over a week ago
Syndicate
Viveve files to sell 5.0M shares of common stock for holders  17:33
06/18/20
06/18
17:33
06/18/20
17:33
VIVE

Viveve

$0.65 /

+0.0115 (+1.80%)

 
ShowHide Related Items >><<
VIVE Viveve
$0.65 /

+0.0115 (+1.80%)

VIVE Viveve
$0.65 /

+0.0115 (+1.80%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
VIVE Viveve
$0.65 /

+0.0115 (+1.80%)

Over a month ago
Syndicate
Viveve files to sell 5.06M shares of common stock for holders  16:32
05/14/20
05/14
16:32
05/14/20
16:32
VIVE

Viveve

$0.63 /

+0.0103 (+1.67%)

 
ShowHide Related Items >><<
VIVE Viveve
$0.63 /

+0.0103 (+1.67%)

VIVE Viveve
$0.63 /

+0.0103 (+1.67%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
VIVE Viveve
$0.63 /

+0.0103 (+1.67%)

Options
Four new option listings and thirteen option delistings on April 20th » 08:30
04/20/20
04/20
08:30
04/20/20
08:30
MSGS

MSG Sports

$237.50 /

+6.9 (+2.99%)

, ALIM

Alimera Sciences

$5.45 /

+0.65 (+13.54%)

, BASX

Basic Energy Services

$0.00 /

+ (+0.00%)

, CYOU

Changyou.com

$10.76 /

+0.005 (+0.05%)

, FVE

Five Star Senior Living

$3.44 /

+0.23 (+7.17%)

, MSG

Madison Square Garden

/

+

, SMTA

Spirit MTA REIT

$0.00 /

+ (+0.00%)

, TGE

Tallgrass Energy

$22.39 /

+ (+0.00%)

, VIVE

Viveve

$0.57 /

-0.0987 (-14.79%)

New option listings for…

New option listings for April 20th include Pacer US Cash Cows 100 ETF (COWZ), Madison Square Garden Sports Corp (Class A Stock) (MSGS), Pacer Trendpilot 100 ETF (PTNQ), and Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF (SRVR). Option delistings effective April 20th include Alimera Sciences (ALIM), Approach Resources Inc (AREXQ), AU Optronics Corp (AUOTY), Basic Energy Services Inc New (BASX), Changyou com Limited (ADS) (CYOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX), Freds Inc (FREDQ), Five Star Quality (FVE), Key Energy Services Inc (KEGX), Madison Square Garden Company New (Class A Stock) (MSG), Spirit MTA (SMTA), Tallgrass Energy LP (Class A Stock) (TGE), and Viveve (VIVE).

ShowHide Related Items >><<
MSGS MSG Sports
$237.50 /

+6.9 (+2.99%)

04/20/20 Imperial Capital
MSG Sports price target lowered to $194 from $308 at Imperial Capital
ALIM Alimera Sciences
$5.45 /

+0.65 (+13.54%)

04/07/20 B. Riley FBR
Alimera Sciences price target lowered to $15 from $24 at B. Riley FBR
01/08/20 B. Riley FBR
B. Riley FBR highlights six Specialty Pharma stocks for 2020
09/30/19 B. Riley FBR
Alimera checks show 'substantial' recovery in Q3, says B. Riley FBR
05/28/19 Craig-Hallum
Alimera Sciences initiated with a Buy at Craig-Hallum
BASX Basic Energy Services
$0.00 /

+ (+0.00%)

03/10/20 Evercore ISI
Basic Energy Services downgraded to In Line from Outperform at Evercore ISI
CYOU Changyou.com
$10.76 /

+0.005 (+0.05%)

04/16/20 Citi
Sohu.com upgraded to Buy from Neutral at Citi
12/02/19 Morgan Stanley
Changyou.com upgraded to Equal Weight from Underweight at Morgan Stanley
08/05/19 Jefferies
Changyou.com initiated with an Underperform at Jefferies
FVE Five Star Senior Living
$3.44 /

+0.23 (+7.17%)

01/16/20 Wells Fargo
Diversified Healthcare Trust cut to Equal Weight from Overweight at Wells Fargo
10/14/19 BofA
Senior Housing resumed with an Underperform at BofA/Merrill
MSG Madison Square Garden
/

+

03/27/20 Imperial Capital
Madison Square Garden price target lowered to $307 from $363 at Imperial Capital
01/24/20
Fly Intel: Top five analyst initiations
01/24/20 Oppenheimer
Madison Square Garden initiated with an Outperform at Oppenheimer
SMTA Spirit MTA REIT
$0.00 /

+ (+0.00%)

06/03/19 Stifel
Hospitality Properties downgraded to Hold from Buy at Stifel
TGE Tallgrass Energy
$22.39 /

+ (+0.00%)

01/07/20 Wells Fargo
Tallgrass Energy downgraded to Underweight at Wells Fargo
01/07/20 Wells Fargo
Tallgrass Energy downgraded to Underweight from Equal Weight at Wells Fargo
10/15/19
Fly Intel: Top five analyst downgrades
10/15/19 Citi
Tallgrass Energy downgraded to Neutral from Buy at Citi
VIVE Viveve
$0.57 /

-0.0987 (-14.79%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
Hot Stocks
Viveve provides business update in response to COVID-19 pandemic » 08:10
04/17/20
04/17
08:10
04/17/20
08:10
VIVE

Viveve

$0.67 /

+0.0325 (+5.12%)

Viveve provided a company…

Viveve provided a company update, including plans to significantly reduce operating expenses and cash burn rate, steps to strengthen its balance sheet and reconfirmation of near-term focus to advance development program for the treatment of stress urinary incontinence, or SUI, in women. In response to COVID-19, Viveve has implemented a range of operational changes designed to support the safety and health of our employees, customers, distribution partners and other contacts as necessary. In addition, the company is implementing a series of significant cost-cutting actions designed to reduce expenses and reposition resources to support the company's current customers and its pivotal clinical development program for cryogen-cooled, Monopolar Radiofrequency, or CMRF, technology in the treatment of SUI. These deliberate actions are tailored to allow the company to re-scale its commercial and operational activities as conditions improve. Viveve also announced a warrant exercise transaction with current company investors and had $9M cash as of the end of the Q1. The financing together with the company's existing cash have strengthened Viveve's balance sheet and provide the resources necessary to maintain the company's business strategy and advance the SUI clinical development plan. The SUI clinical development program and potential label expansion for this indication present an opportunity to address an area of unmet need in women's intimate health for Viveve's CMRF technology. An estimated 25-30 million women worldwide who suffer from the SUI medical condition could potentially benefit from a noninvasive single session treatment with Viveve System, representing an estimated $10B-$12B market opportunity. The reorganized Viveve team is positioned to achieve multiple clinical milestones within the next few months to advance the SUI program. These include the anticipated readout from the three-arm SUI feasibility trial in the late summer of this year and the potential launch of the multicenter, randomized double-blinded, sham controlled SUI trial in the U.S., now entitled PURSUIT pending FDA approval of the company's recently resubmitted IDE. The trial is designed to evaluate the safety and efficacy of Viveve's CMRF treatment versus an inert sham tip for the improvement of SUI in women.

ShowHide Related Items >><<
VIVE Viveve
$0.67 /

+0.0325 (+5.12%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
Hot Stocks
Viveve resubmits IDE to FDA to begin PURSUIT trial » 08:36
04/15/20
04/15
08:36
04/15/20
08:36
VIVE

Viveve

$0.60 /

-0.02 (-3.23%)

Viveve Medical announced…

Viveve Medical announced that the company has resubmitted its investigational device exemption, or IDE, to the FDA for approval to begin a stress urinary incontinence, or SUI, multicenter, randomized, double-blinded, sham-controlled trial now entitled, PURSUIT. The trial is designed to evaluate the safety and efficacy of Viveve's CMRF treatment versus an inert sham tip for the improvement of SUI in women. Following the original IDE submission to conduct a U.S. SUI trial, Viveve completed multiple rounds of discussions with the FDA. Based on these discussons, the resubmitted IDE addresses specific protocol requests and provides positive results from additional in vivo animal safety testing requested by the FDA. The results of the LIBERATE-International SUI study, reported in August of 2019, demonstrated significant and durable improvement across all study endpoints, including nearly an 80% reduction in leakage as measured by one-hour Pad Weight Test at six months. As reported however, patients in the sham arm of the study also demonstrated significant improvement. Based on a significant indiction of efficacy in the treatment arm, Viveve rapidly launched a short-term 3-arm SUI feasibility trial, utilizing a completely inert sham tip, under an approved Investigational Testing Application by the Canadian Ministry of Health. Initiated in January, the SUI feasibility trial completed enrollment in March, and is targeted for readout in late summer of this year. If positive, the results of the SUI feasibility trial could support the launch of the pivotal PURSUIT trial in the U.S. for the improvement of SUI in women.

ShowHide Related Items >><<
VIVE Viveve
$0.60 /

-0.02 (-3.23%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
Over a quarter ago
Hot Stocks
Viveve announces VIVEVE II trial did not meet primary endpoint » 08:40
04/09/20
04/09
08:40
04/09/20
08:40
VIVE

Viveve

$0.87 /

+0.1584 (+22.31%)

Viveve announced topline…

Viveve announced topline results from the VIVEVE II clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of the company's proprietary, cryogen-cooled monopolar radiofrequenc, or CMRF, technology for the improvement of sexual function in women following vaginal childbirth. The VIVEVE II study did not meet its primary endpoint of demonstrating a statistically significant improvement in the mean change from baseline in total Female Sexual Function Index score at 12 months. The study included 220 subjects that successfully completed 12-month follow-up. Subjects were randomized in a 1:1 ratio for the active and the sham treatments at 17 clinical sites in the United States. Adjusted mean change for the active group was 9.8 and the adjusted mean change for the sham group was 9, a difference of 0.8. There were no serious device-related adverse events reported. The treatment groups were well balanced, and the number of subjects lost to follow-up was as expected. In light of the VIVEVE II trial outcome and the current COVID-19 pandemic, the company is currently evaluating strategic alternatives, as well as actively assessing its current organization and cost structure.

ShowHide Related Items >><<
VIVE Viveve
$0.87 /

+0.1584 (+22.31%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
Hot Stocks
Viveve 2.0 system issued licence by Health Canada » 14:28
04/08/20
04/08
14:28
04/08/20
14:28
VIVE

Viveve

$0.85 /

+0.14 (+19.72%)

A post to the website of…

A post to the website of Health Canada shows that the Viveve 2.0 system was issued a licence in Canada on April 6. Reference Link

ShowHide Related Items >><<
VIVE Viveve
$0.85 /

+0.14 (+19.72%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
Hot Stocks
Viveve receives registration clearance from Taiwanese FDA for CMRF system, tips » 08:34
03/26/20
03/26
08:34
03/26/20
08:34
VIVE

Viveve

$0.64 /

+0.0395 (+6.58%)

Viveve announced…

Viveve announced registration clearance from the Taiwanese FDA for the company's next-generation Viveve 2.0 Cryogen-cooled Monopolar Radiofrequency, or CMRF, system and consumable treatment tips for use in general surgical procedures for electrocoagulation and hemostasis.

ShowHide Related Items >><<
VIVE Viveve
$0.64 /

+0.0395 (+6.58%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim
Hot Stocks
Viveve announces completion of participation in VIVEVE II trial » 08:32
03/12/20
03/12
08:32
03/12/20
08:32
VIVE

Viveve

$0.81 /

-0.09 (-10.00%)

Viveve announced that all…

Viveve announced that all patients have now completed participation in the VIVEVE II pivotal FDA clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of the company's proprietary, Cryogen-cooled Monopolar Radiofrequency technology for the improvement of sexual function in women following vaginal childbirth.

ShowHide Related Items >><<
VIVE Viveve
$0.81 /

-0.09 (-10.00%)

12/03/19 Ladenburg
Viveve upgraded to Buy from Neutral at Ladenburg
07/24/19 Ladenburg
Viveve downgraded to Neutral from Buy at Ladenburg
07/23/19
Fly Intel: Top five analyst downgrades
07/23/19 Maxim
Viveve downgraded to Hold from Buy at Maxim

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.